186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases
Han, S.H.; De Klerk, J.M.; Zonnenberg, B.A.; Tan, S.; Van Rijk, P.P.
Quarterly Journal of Nuclear Medicine Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology 45(1): 84-90
2001
ISSN/ISBN: 1125-0135 PMID: 11456380 Document Number: 534463
Pain palliation with bone-seeking radiopharmaceuticals is an effective treatment modality in patients with advanced metastatic bone cancer. Several studies have shown encouraging clinical results of palliative therapy using 186Re-HEDP, with an overall reported response rate of +/-71% for painful osseous metastasized prostate and breast cancer patients. 186Re-HEDP is a very potential isotope with numerous advantageous characteristics for this purpose. Myelosuppressive toxicity is limited and reversible, which makes repetitive treatment safe. However, individual studies are difficult to compare, and are hampered by the numerous and different methods used to assess clinical response. Standardized clinical response assessment using the objective multi-dimensional pain evaluation model should therefore be implemented.